WHO ICTRP trial
A phase Ib/II, multicenter, open label, study of LEE011 in combination with…
NL-OMON44775 · Overview of Medical Research in the Netherlands (NL-OMON) · Not Recruiting
Key facts
| Trial ID | NL-OMON44775 |
|---|---|
| Public title | A phase Ib/II, multicenter, open label, study of LEE011 in combination with MEK162 in adult patients with NRAS mutant melanoma |
| Scientific title | A phase Ib/II, multicenter, open label, study of LEE011 in combination with MEK162 in adult patients with NRAS mutant melanoma - LEE011 with MEK162 in NRAS mutant melanoma (CMEK162X2114) |
| Primary sponsor | Array Biopharma |
| Registry | Overview of Medical Research in the Netherlands (NL-OMON) |
| Recruitment status | Not Recruiting |
| Study type | Interventional |
| Countries | Australia;Germany;Italy;Netherlands;Norway;United States of America |
| Conditions | malignant cutaneous melanoma skin cancer;10040900;malignant cutaneous melanoma;skin cancer |
| Interventions | Treatment with MEK162 and LEE011 LEE011 capsules, once daily first 3 weeks of each cycle and one week no intake. Starting dose: 200mg MEK162 tablets, twice daily , every day. Starting dose: 45mg ;LEE011;MEK162;NRAS melanoma |
| Registration date | Jun 8, 2017 |
| Target size | 10 |
| Secondary IDs | 2012-004104-35;NCT01781572;NL43662.091.13 |
| Registry page | onderzoekmetmensen.nl |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: